Summary:
In postmenopausal osteoporotic patients with and without type 2 diabetes mellitus, rhPTH(1-34) treatment significantly improved bone mineral density (BMD) and increased markers of bone turnover compared to alendronate (ALN) or placebo treatments, though it was associated with no notable adverse effects reported during the one-year study period.
| PICO | Description |
|---|---|
| Population | Postmenopausal women with osteoporosis (OP), both with and without type 2 diabetes mellitus (T2DM), as well as C57BL/6 mice with diet and streptozotocin-induced T2DM. |
| Intervention | Administration of recombinant human parathyroid hormone rhPTH(1-34) in both animal models and human subjects over one year (clinical trial duration). |
| Comparison | Alendronate (ALN) treatment or normal saline in animal models; ALN in clinical trial participants. |
| Outcome | rhPTH(1-34) significantly improved lumbar spine BMD and enhanced bone turnover markers (P1NP, CTX, osteocalcin) in diabetic osteoporotic patients and animal models. ALN produced smaller improvements in BMD, particularly in patients with both OP and T2DM, and did not effectively reverse low bone turnover. |
Source: Huijuan Li, et al. “Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease.” Read article here.
